Invitrogen™ Lumiliximab Recombinant Monoclonal Antibody

CD23 is a 45 kDa glycoprotein that serves as a low-affinity receptor for IgE, playing a crucial role in regulating IgE responses and B cell activation. It is expressed on mature B cells, mantle zone B cells, follicular dendritic cells, and at lower levels on T cells, NK cells, Langerhans cells, and platelets. CD23 expression is upregulated upon B cell activation, and its soluble forms are biologically active, acting as potent mitogenic factors. CD23 is strongly expressed on Epstein-Barr virus (EBV)-transformed B lymphoblasts and is present on a subpopulation of freshly isolated peripheral blood and tonsil B cells. It is also detected in neoplastic cells from cases of B cell chronic lymphocytic leukemia and some centroblastic/centrocytic lymphomas. Functionally, CD23 is involved in B cell growth, differentiation, and IgE production. It interacts with CD21 and the alpha subunits of CD11b and CD11c, further influencing immune responses. Diseases associated with CD23 dysfunction include chronic conjunctivitis and chronic lymphocytic leukemia, highlighting its importance in both normal immune function and disease states. This makes CD23 a valuable target for antibody customers interested in B-cell-related research and diagnostics.